Volume | 7,422,179 |
|
|||||
News | - | ||||||
Day High | 15.80 | Low High |
|||||
Day Low | 15.03 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Catalyst Pharmaceuticals Inc | CPRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
15.34 | 15.03 | 15.80 | 15.13 | 15.34 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
28,028 | 7,422,179 | $ 15.41 | $ 114,398,587 | - | 11.09 - 17.78 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:55 | 9 | $ 15.17 | USD |
Catalyst Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.78B | 117.86M | - | 398.2M | 71.41M | 0.61 | 24.99 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Catalyst Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CPRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.86 | 16.25 | 15.03 | 15.52 | 1,187,301 | -0.6996 | -4.41% |
1 Month | 16.60 | 16.665 | 14.97 | 15.64 | 1,037,503 | -1.44 | -8.67% |
3 Months | 14.50 | 17.495 | 13.1161 | 15.29 | 1,261,926 | 0.6604 | 4.55% |
6 Months | 13.29 | 17.495 | 11.89 | 14.68 | 1,371,103 | 1.87 | 14.07% |
1 Year | 17.74 | 17.78 | 11.09 | 14.01 | 1,471,241 | -2.58 | -14.54% |
3 Years | 4.38 | 22.11 | 4.281 | 12.33 | 1,606,261 | 10.78 | 246.13% |
5 Years | 5.32 | 22.11 | 2.235 | 8.64 | 1,764,713 | 9.84 | 184.97% |
Catalyst Pharmaceuticals Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |